News

Published on 9 May 2024 on Insider Monkey via Yahoo Finance

Editas Medicine, Inc. (NASDAQ:EDIT) Q1 2024 Earnings Call Transcript


Article preview image

Editas Medicine, Inc. (NASDAQ:EDIT) Q1 2024 Earnings Call Transcript May 8, 2024

Editas Medicine, Inc. misses on earnings expectations. Reported EPS is $-0.76 EPS, expectations were $-0.63. Editas Medicine, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here).

Operator: Good morning, and welcome to the Editas Medicine's First Quarter 2024 Conference Call. All participants are now in a listen-only mode. There will be a question-and-answer session at the end of this call. Please be advised that this call is being recorded at the company's request. I would now like to turn the call over to Cristi Barnett, Corporate Communications and Investor Relations at Editas Medicine.

NASDAQ.EDIT price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Is Editas Medicine, Inc. (EDIT) a Promising Gene Editing Stock?

We recently published a list of 10 Most Promising Gene Editing Stocks to Buy According to Hedge...

Insider Monkey · via Yahoo Finance 31 Oct 2024

State Street Corp's Strategic Reduction in Editas Medicine Inc Holdings

Overview of Recent Transaction by State Street Corp On September 30, 2024, State Street Corp exec...

GuruFocus.com · via Yahoo Finance 17 Oct 2024

What Makes Editas Medicine, Inc. (EDIT) One of the Best Small-Cap Stocks with...

We recently compiled a list of the Top 10 Small-Cap Stocks with Highest Upside Potential. In this...

Insider Monkey · via Yahoo Finance 19 Jun 2024

Is Editas Medicine, Inc. (EDIT) One of the Best Biotech Penny Stocks to Buy Now?

We recently compiled a list of the 10 Best Biotech Penny Stocks to Buy Now. In this article, we a...

Insider Monkey · via Yahoo Finance 19 Jun 2024

EVP, Chief Financial Officer Erick Lucera Sells 22,337 Shares of Editas Medicine Inc

Erick Lucera, the EVP, Chief Financial Officer of Editas Medicine Inc (NASDAQ:EDIT), sold 22,337 ...

GuruFocus.com via Yahoo Finance 23 May 2024

Director Jessica Hopfield Acquires 45,000 Shares of Editas Medicine Inc

On May 13, 2024, Jessica Hopfield, Director at Editas Medicine Inc (NASDAQ:EDIT), purchased 45,00...

GuruFocus.com via Yahoo Finance 16 May 2024

Editas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest...

Editas Medicine, Inc. (NASDAQ:EDIT) just released its latest quarterly report and things are not ...

Simply Wall St. via Yahoo Finance 9 May 2024

Editas (EDIT) Q1 Earnings & Revenues Lag Estimates, Stock Down

Editas Medicine, Inc. EDIT incurred a loss of 76 cents per share in the first quarter of 2024, wi...

Zacks via Yahoo Finance 9 May 2024

Editas Medicine, Inc. (NASDAQ:EDIT) Q1 2024 Earnings Call Transcript

Editas Medicine, Inc. (NASDAQ:EDIT) Q1 2024 Earnings Call Transcript May 8, 2024 Editas Medicine,...

Insider Monkey via Yahoo Finance 9 May 2024

CHOP restored eyesight for two children with one injection. It’s one more step for gene editing...

The 10-year-old and 14-year-old patients had their eyesight improved about 10- to 100-fold after ...

Philly.com 7 May 2024